{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:41:15Z","timestamp":1793832075949,"version":"4.6.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamaophthalmol.2021.4585","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T11:02:46Z","timestamp":1637751766000},"page":"20","source":"Crossref","is-referenced-by-count":105,"title":["Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"140","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[{"name":"Sierra Eye Associates, Reno, Nevada"},{"name":"Reno School of Medicine, University of Nevada, Reno"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Zarbin","sequence":"additional","affiliation":[{"name":"Institute of Ophthalmology and Visual Science, Rutgers\u2013New Jersey Medical School, Rutgers University, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[{"name":"Retinal Consultants of Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Albini","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"B","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Agashivala","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin S.","family":"Yu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston"},{"name":"Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew W.","family":"MacCumber","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology at Rush University Medical Center, Chicago, Illinois"},{"name":"Illinois Retina Associates, SC, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"eoi210067r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-Related Macular Degeneration Preferred Practice Pattern\u00ae.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi210067r4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/OPTH","article-title":"Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration.","volume":"13","author":"Yannuzzi","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"eoi210067r5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi210067r6","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"eoi210067r7","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"4","key":"eoi210067r8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab.","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis"},{"issue":"10","key":"eoi210067r9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab.","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi210067r11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER.","volume":"128","author":"Mones","year":"2021","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi210067r12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ophtha.2017.08.035","article-title":"The American Academy of Ophthalmology\u2019s IRIS\u00ae Registry (Intelligent Research in Sight Clinical Data): a look back and a look to the future.","volume":"124","author":"Parke","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi210067r13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry.","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi210067r16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early experience with brolucizumab treatment of neovascular age-related macular degeneration.","volume":"139","author":"Enr\u00edquez","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"eoi210067r17","first-page":"456","article-title":"Real-world efficacy and safety of brolucizumab.","volume":"62","author":"Walter","year":"2021","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"eoi210067r18","first-page":"286","article-title":"A retrospective study on the use of brolucizumab for the treatment of NVAMD: a 1-year private practice experience.","volume":"62","author":"Hamou","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"eoi210067r19","first-page":"451","article-title":"Real world efficacy and safety of brolucizumab in neovascular AMD: the REBEL study.","volume":"62","author":"Aziz","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"eoi210067r20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA.","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"eoi210067r21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/bjo.2005.083725","article-title":"Risks of relapse in patients with acute anterior uveitis.","volume":"91","author":"Natkunarajah","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"eoi210067r22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ajo.2020.12.013","article-title":"Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment.","volume":"224","author":"Braun","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"eoi210067r23","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ophtha.2011.02.044","article-title":"Risk of relapse in primary acute anterior uveitis.","volume":"118","author":"Grunwald","year":"2011","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi210067r24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and\/or vascular occlusion after brolucizumab treatment.","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"eoi210067r25","first-page":"1","article-title":"The impact of COVID-19 on intravitreal injection compliance.","author":"Wasser","year":"2020","journal-title":"SN Compr Clin Med"},{"issue":"3","key":"eoi210067r26","first-page":"1","article-title":"Effect of COVID-19 pandemic on anti-VEGF treatment of medical retinal conditions\u2014an audit.","volume":"6","author":"Rahimzadeh","year":"2021","journal-title":"The Physician"},{"key":"eoi210067r27","doi-asserted-by":"crossref","DOI":"10.1177\/11206721211010613","article-title":"Treatment of neovascular age related macular degeneration during COVID-19 pandemic: the short term consequences of unintended lapses.","author":"Sekeroglu","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"eoi210067r3","author":"Novartis Pharmaceuticals Corporation","year":"2020"},{"key":"eoi210067r1","unstructured":"Centers for Disease Control and Prevention. Common eye disorders. Updated June 3, 2020. Accessed October 15, 2020. https:\/\/www.cdc.gov\/visionhealth\/basics\/ced\/index.html"},{"key":"eoi210067r10","unstructured":"Holzner? J. Subspecialty news: a label change for Beovu, AI for AMD, clinical trial data, and more. Published July 1, 2020. Accessed October 4, 2021. https:\/\/www.retinalphysician.com\/issues\/2020\/july-august-2020\/subspecialty-news-a-label-change-for-beovu,-ai-for"},{"key":"eoi210067r14","unstructured":"American Academy of Ophthalmology. IRIS Registry. Published 2020. Accessed November 5, 2020. https:\/\/www.aao.org\/iris-registry\/about."},{"key":"eoi210067r15","unstructured":"Komodo Health. Homepage. Published 2020. Accessed November 5, 2020. https:\/\/www.komodohealth.com\/"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2786559\/jamaophthalmology_khanani_2021_oi_210067_1641846882.96138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T11:08:50Z","timestamp":1642676930000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2786559"}},"subtitle":["Results From the IRIS Registry and Komodo Healthcare Map"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.4585","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}